Overexpression of a Mycobacterium ulcerans Ag85B-EsxH Fusion Protein in Recombinant BCG Improves Experimental Buruli Ulcer Vaccine Efficacy

Buruli ulcer (BU) vaccine design faces similar challenges to those observed during development of prophylactic tuberculosis treatments. Multiple BU vaccine candidates, based upon Mycobacterium bovis BCG, altered Mycobacterium ulcerans (MU) cells, recombinant MU DNA, or MU protein prime-boosts, have...

Descripción completa

Detalles Bibliográficos
Autores principales: Hart, Bryan E., Lee, Sunhee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5179062/
https://www.ncbi.nlm.nih.gov/pubmed/27941982
http://dx.doi.org/10.1371/journal.pntd.0005229

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5179062/
https://www.ncbi.nlm.nih.gov/pubmed/27941982
http://dx.doi.org/10.1371/journal.pntd.0005229

Ejemplares similares